Skip to content
CAR T-cell therapy is a worldwide cancer breakthrough. And UChicago Medicine is the first to offer it in Chicago.

CAR T-cell Therapy

A revolutionary cancer breakthrough. UChicago Medicine is the first place in Chicago to offer it.

Request an Appointment

Supercharging Your Blood Cells to Defeat Cancer

There’s a breakthrough in the fight against cancer, and it’s making headlines around the world. Called CAR T-cell therapy, the treatment supercharges a patient’s white blood cells to seek out and destroy cancer cells. Research at UChicago Medicine played a key role in the development of this exciting new immunotherapy for advanced blood cancers.  

Select medical centers in the United States, including UChicago Medicine, led clinical trials of this new treatment for leukemia and lymphoma. After promising — and, in some cases, remarkable — results in adults and children, the FDA has approved CAR T-cell therapy for the treatment of specific types of these blood cancers. UChicago Medicine is the first site in the country to be certified for FDA-approved CAR T-cell therapies for specific blood cancers in both adult and pediatric patients. 

What Is CAR T-cell Therapy?

CAR (Chimeric Antigen Receptor) T-cell therapy is an emerging form of cancer immunotherapy, which involves supercharging a patient’s T cells to recognize and attack cancer cells. 

During clinical trials of CAR T-cell therapy, 70 to 90 percent of patients with acute lymphoblastic leukemia (ALL) went into remission after this treatment. Forty to 50 percent of patients with non-Hodgkin lymphoma experienced complete remission. While it’s too early to say these patients are cured, the results are encouraging for individuals with hard-to-treat (refractory) or relapsed leukemia or lymphoma. Learn more about how CAR T-cell therapy works. 
Scott McIntyre was the first patient to receive CAR T-cell therapy at UChicago Medicine. See his story. 

UChicago Medicine Cancer Care Locations

Request an Appointment for CAR T-Cell Therapy

* Required Field